Diurnal completes IPO in dark days of December
Diurnal Group, a UK company developing drugs to treat rare chronic hormonal imbalances, completed its Aim IPO for £25m on Monday, gaining a £75m market cap.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts